EFFECT OF OMEPRAZOLE AND LANSOPRAZOLE ON SERUM PEPSINOGEN-A LEVELS IN PATIENTS WITH DUODENAL-ULCER

被引:1
作者
CHANG, FY [1 ]
LEE, CT [1 ]
CHIANG, CY [1 ]
LEE, SD [1 ]
机构
[1] NATL YANG MING UNIV,TAIPEI,TAIWAN
来源
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 1995年 / 56卷 / 09期
关键词
D O I
10.1016/0011-393X(95)85092-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We compared the magnitudes of elevated serum pepsinogen A levels in patients receiving short-term therapy with two proton pump inhibitors for duodenal ulcer. The reversibilities of the elevated levels were evaluated after withdrawal of medications. Patients with active duodenal ulcer received for 4 weeks either 30-mg lansoprazole (n = 42) or 20-mg omeprazole (n = 41) once daily. Four weeks after treatment was discontinued, ulcer healing was seen in 95.2% of patients taking lansoprazoIe and 92.7% of patients taking omeprazole, Both agents led to the marked elevation of serum pepsinogen A levels on day 29 with an equivalent magnitude (2.33 +/- 0.56 vs 2.3 +/- 0.69-fold; NS), The magnitudes of pepsinogen A elevation during Helicobacter pylori elimination were markedly higher than those exhibited when H pylori was not eliminated (P < 0.05). All elevations returned to their baseline levels 4 weeks after the cessation of treatment. We conclude that the standard dosages of both proton pump inhibitors yield an equal healing efficacy and the same magnitude of temporary elevation of serum pepsinogen A levels in duodenal ulcer patients. Patients in whom H pylori was eliminated exhibited a higher incidence of hyperpepsinogenemia A.
引用
收藏
页码:887 / 893
页数:7
相关论文
共 50 条
[41]   SERUM PEPSINOGEN-I AND DUODENAL-ULCER IN LIVER-CIRRHOSIS [J].
BASILICO, M ;
BONATO, C ;
BOCCHIA, P ;
BALLARIN, E ;
MALESCI, A .
GASTROENTEROLOGY, 1986, 90 (05) :1338-1338
[42]   OPTIMAL DOSE OF OMEPRAZOLE IN DUODENAL-ULCER [J].
SAVARINO, V ;
MELA, GS ;
VIGNERI, S ;
CELLE, G .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1993, 5 (04) :296-297
[43]   ELEVATED SERUM PEPSINOGEN-I AND PEPSINOGEN-II LEVELS DIFFER AS RISK-FACTORS FOR DUODENAL-ULCER AND GASTRIC-ULCER [J].
SAMLOFF, IM ;
STEMMERMANN, GN ;
HEILBRUN, LK ;
NOMURA, A .
GASTROENTEROLOGY, 1986, 90 (03) :570-576
[44]   OMEPRAZOLE IN THE MANAGEMENT OF REFRACTORY DUODENAL-ULCER [J].
BARDHAN, KD .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :63-75
[45]   THE MAINTENANCE TREATMENT OF DUODENAL-ULCER WITH OMEPRAZOLE [J].
DELPIANO, M ;
MANFREDDA, I ;
MONTINO, F ;
OCCHIPINTI, P .
GASTROINTESTINAL ENDOSCOPY, 1993, 39 (02) :273-273
[46]   SERUM PEPSINOGEN-I LEVELS AND HLA-B22 - A GENETIC ASSOCIATION IN A SUBGROUP OF DUODENAL-ULCER PATIENTS [J].
VENTURI, C ;
BORTOLAMI, M ;
DIMARIO, F ;
DELAZZARI, F ;
VIANELLO, F ;
FARINATI, F ;
PLEBANI, M ;
NACCARATO, R .
ITALIAN JOURNAL OF GASTROENTEROLOGY, 1986, 18 (02) :77-78
[47]   THE EFFECT OF OMEPRAZOLE AND RANITIDINE ON ULCER HEALING IN TREATMENT OF DUODENAL-ULCER PATIENTS - A SWEDISH MULTICENTER STUDY [J].
HALLBERG, D ;
BACKMAN, L ;
HELLSTROM, M ;
MOBERG, S ;
REICHARD, H ;
LINDHOLMER, C ;
FENYO, G ;
NYSTROM, B .
DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (10) :S280-S280
[48]   ACUTE TREATMENT OF DUODENAL-ULCER - EXPERIENCE WITH LANSOPRAZOLE [J].
MIGNON, M ;
VALLOT, T .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1993, 7 :37-40
[49]   PEPSINOGEN GENETICS AND DUODENAL-ULCER DISEASE - REPLY [J].
HABIBULLAH, CM ;
ALI, MM ;
ISHAQ, M ;
SALEEM, Y .
GUT, 1986, 27 (02) :225-226
[50]   BLOOD PEPSINOGEN AS A SUBCLINICAL MARKER FOR DUODENAL-ULCER [J].
DOTTO, P ;
VIANELLO, F ;
DELBIANCO, T ;
LAINO, G ;
BATTAGLIA, G ;
GION, M ;
KUSSTATSCHER, S ;
DELFAVERO, G ;
PLEBANI, M ;
DIMARIO, F .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 54 (02) :172-176